Abstracts Archive - Page 2390 of 2425 - ACR Meeting Abstracts

Abstract Number: 484 • 2012 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
Jipan Xie¹, Arijit Ganguli², Hongbo Yang¹, Kejal Parikh¹, Eric Q. Wu¹ and Mary Cifaldi³, ¹Analysis Group Inc., Boston, MA, ²AbbVie, North Chicago, IL, ³Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) and etanercept (ETN) are two commonly used tumor necrosis factor (TNF)-α antagonists for the treatment of rheumatoid arthritis (RA). The study is…
Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Mathieu Verdet¹, Clément Guillou², Marie-Laure Potier², Martine Hiron², Fabienne Jouen³, Olivier Boyer⁴, Thierry Lequerré⁵ and Olivier Vittecoq⁶, ¹Rheumatology, Rouen University Hospital, Bois Guillaume, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Immunology, Rouen University Hospital, Rouen Cedex, France, ⁴Immunology, INSERM U905, University of Rouen, Rouen, France, ⁵Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
Abstract Number: 486 • 2012 ACR/ARHP Annual Meeting
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
Daniel Furst¹, Ana P. Lacerda², Nupun Andhivarothai³, Jasmina Kalabic⁴ and Neelufar Mozaffarian³, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Abbott Laboratories, São Paulo, Brazil, ³Abbott Laboratories, Abbott Park, IL, ⁴Abbott GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: The systemic inflammation of rheumatoid arthritis (RA) can have detrimental effects on the hematopoietic and cardiovascular systems. Additionally, effective DMARD treatments for RA can…
Abstract Number: 487 • 2012 ACR/ARHP Annual Meeting
Functional Disability in Early Rheumatoid Arthritis – Contributions of Disease Activity and Structural Damage, and the Impact of Different Treatment Strategies
Josef S. Smolen¹, Roy Fleischmann², Paul Emery³, Ronald F. van Vollenhoven⁴, Stefan Florentinus⁵, Freddy Faccin⁶, Suchitrita S. Rathmann⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Abbott Laboratories, Abbott Park, IL, ⁸Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁹UCSD School of Medicine, La Jolla, CA
Background/Purpose: Functional impairment among patients with rheumatoid arthritis (RA) can be conceptualized as consisting of a reversible component that relates to disease activity (ACT-HAQ) and…
Abstract Number: 488 • 2012 ACR/ARHP Annual Meeting
Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
Beenish Nafees¹, Andrew Lloyd¹, Carol L. Gaich², Julie Birt² and Rodney A. Hughes³, ¹Late Phase & Outcomes Research, Oxford Outcomes, Oxford, United Kingdom, ²Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) and their physicians face a range of treatment choices. The treatments that patients receive should be driven partly by…
Abstract Number: 489 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell³, Lang Chen⁴, Shuo Yang⁵, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Health Care Organization & Policy, University of Alabama-Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evaluating the real world effectiveness of biologic DMARDs in rheumatoid arthritis (RA) patients using administrative claims data has previously not been feasible due to…
Abstract Number: 450 • 2012 ACR/ARHP Annual Meeting
Late Onset Neutropenia After Rituximab Treatment for Rheumatological Conditions
Gabriel S. Breuer¹, Michael Z. Ehrenfeld², Itzhak Rosner³, Alexandra Balbir-Gurman⁴, Devy Zisman⁵ and Daphna Paran⁶, ¹Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Dept of Med C & Rheum Dis Unit, Chaim Sheba Medical Center, Tel HaShomer, Israel, ³Rheumatology, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel, ⁴B. Shine Rheumatology Unit, Rambam Health Care Campus, Bruce, Haifa, Israel, ⁵Dept of Internal Medicine, Carmel Medical Center, Haifa, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel Aviv, Israel
Background/Purpose: Rituximab is a monoclonal chimeric antibody targeting the CD20 on the surface of normal and abnormal maturing B cells. Late onset neutropenia (LON) is…
Abstract Number: 451 • 2012 ACR/ARHP Annual Meeting
Pilot Study of Stimulation of the Cholinergic Anti-Inflammatory Pathway with an Implantable Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis
Frieda A. Koopman¹, Sanda Miljko², Simeon Grazio³, Sekib Sokolovic⁴, Kevin Tracey⁵, Yaakov Levine⁶, Ralph Zitnik⁶ and Paul-Peter Tak⁷, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²University Clinical Hospital, Mostar, Bosnia, ³Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ⁴Rheumatology, University Clinical Center, Sarajevo, Bosnia, ⁵Feinstein Institute for Medical Research, Manhasset, NY, ⁶SetPoint Medical Corporation, Valencia, CA, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: The inflammatory reflex regulates innate and adaptive immunity (Andersson O, Tracey K, Annu. Rev. Immunol. 2012; 30:313). Activation of its efferent arm (the Cholinergic…
Abstract Number: 452 • 2012 ACR/ARHP Annual Meeting
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
Daniele F. Pereira¹, Rita N.V. Furtado², Natalia P. Machado³ and Jamil Natour⁴, ¹Disciplina de Reumatologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Disciplina de Reumatologia, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The optimal dose of corticosteroid to be used in intraarticular injection is not well established. The objective of this study is to compare the…
Abstract Number: 453 • 2012 ACR/ARHP Annual Meeting
Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose
Susanna Proudman¹, Llew Spargo¹, Cindy Hall¹, Leah McWilliams¹, Anita Lee¹, Maureen Rischmueller², Robert Gibson³, Michael James¹ and Leslie G. Cleland¹, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: The symptomatic benefit and NSAID-sparing effects of fish oil (FO) in RA are well known but effects on disease outcomes are less well established,…
Abstract Number: 454 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
Graeme Jones¹, Anthony Sebba², Denise Lepley³, Jenny Devenport⁴, Corrado Bernasconi⁵, Devi Smart⁶, Chiedzo Mpofu⁷ and Juan J. Gomez-Reino⁸, ¹Musculoskeletal, Menzies Research Institute Tasmania, Hobart, Australia, ²University of South Florida, Tampa, FL, ³Medical Affairs Immunology, Genentech, South San Francisco, CA, ⁴Genentech, South San Francisco, CA, ⁵Consultant, Basel, Switzerland, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Roche, Basel, Switzerland, ⁸Rheumatology, Hospital Clinico Universitario, Santiago, Spain
Background/Purpose: Treatment with tocilizumab (TCZ) monotherapy has been studied in 3 randomized clinical trials: AMBITION,1 ACT-RAY,2 and ADACTA.3 AMBITION1 was the first trial to demonstrate…
Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Keisuke Izumi¹, Yuko Kaneko², Hidekata Yasuoka³, Noriyuki Seta⁴, Hideto Kameda⁵, Masataka Kuwana⁵ and Tsutomu Takeuchi⁶, ¹Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Keio university, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…
Abstract Number: 456 • 2012 ACR/ARHP Annual Meeting
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study
Axel Finckh¹, Jacques-Eric Gottenberg², Chiedzo Mpofu³, William G. Bensen⁴, Andrea Rubbert-Roth⁵, Fedra Irazoque⁶, Victor Martínez Taboada⁷, Carol Chung⁸, Lykke Hinsch-Gylvin³, Clodoveo Ferri⁹ and Paul Emery¹⁰, ¹Department of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland, ²Strasbourg University Hospital, Strasbourg, France, ³F Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Internal Medicine I, University of Cologne, Cologne, Germany, ⁶Servicio de Reumatología, Hospital Angeles Mocel, Mexico City, Mexico, ⁷Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Genentech Inc., South San Francisco, CA, ⁹Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹⁰Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: SWITCH-RA is a global, observational study evaluating the effectiveness of switching to an alternative TNFi or rituximab (RTX) following initial TNFi failure in patients…
Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Jean-Pascal Roussy¹, Louis Bessette², Sasha Bernatsky³, Elham Rahme⁴ and Jean Lachaine¹, ¹Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…
Abstract Number: 458 • 2012 ACR/ARHP Annual Meeting
Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database
Denis Choquette¹, Diane Sauvageau², Boulos Haraoui² and Jean-Pierre Raynauld², ¹Rheumatology, Institut de Rhumatologie De Montréal, Montreal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Anti-TNF agents have been in used in Canada for the last ten years. Although a vast body of clinical experience has been accumulated since…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].